Clinical implications of dose to functional lung volumes in the trimodality treatment of esophageal cancer.


Journal

Acta oncologica (Stockholm, Sweden)
ISSN: 1651-226X
Titre abrégé: Acta Oncol
Pays: England
ID NLM: 8709065

Informations de publication

Date de publication:
Nov 2023
Historique:
medline: 8 11 2023
pubmed: 29 8 2023
entrez: 29 8 2023
Statut: ppublish

Résumé

Trimodality treatment, i.e., neoadjuvant chemoradiotherapy (nCRT) followed by surgery, for locally advanced esophageal cancer (EC) improves overall survival but also increases the risk of postoperative pulmonary complications. Here, we tried to identify a relation between dose to functional lung volumes (FLV) as determined by 4D-CT scans in EC patients and treatment-related lung toxicity. All patients with EC undergoing trimodality treatment between 2017 and 2022 in UZ Leuven and scanned with 4D-CT-simulation were selected. FLVs were determined based on Jacobian determinants of deformable image registration between maximum inspiration and expiration phases. Dose/volume parameters of the anatomical lung volume (ALV) and FLV were compared between patients with versus without postoperative pulmonary complications. Results of pre- and post-nCRT pulmonary function tests (PFTs) were collected and compared in relation to radiation dose. Twelve out of 51 EC patients developed postoperative pulmonary complications. ALV was smaller while FLV10Gy and FLV20Gy were larger in patients with complications (respectively 3141 ± 858mL vs 3601 ± 635mL, Small ALV and increasing FLV exposed to intermediate (10 to 20 Gy) dose are associated to postoperative pulmonary complications. Changes of DLCO occur during nCRT but do not seem to be related to radiation dose to ALV or FLV. This information could attribute towards toxicity risk prediction and reduction strategies for EC.

Sections du résumé

BACKGROUND UNASSIGNED
Trimodality treatment, i.e., neoadjuvant chemoradiotherapy (nCRT) followed by surgery, for locally advanced esophageal cancer (EC) improves overall survival but also increases the risk of postoperative pulmonary complications. Here, we tried to identify a relation between dose to functional lung volumes (FLV) as determined by 4D-CT scans in EC patients and treatment-related lung toxicity.
MATERIALS AND METHODS UNASSIGNED
All patients with EC undergoing trimodality treatment between 2017 and 2022 in UZ Leuven and scanned with 4D-CT-simulation were selected. FLVs were determined based on Jacobian determinants of deformable image registration between maximum inspiration and expiration phases. Dose/volume parameters of the anatomical lung volume (ALV) and FLV were compared between patients with versus without postoperative pulmonary complications. Results of pre- and post-nCRT pulmonary function tests (PFTs) were collected and compared in relation to radiation dose.
RESULTS UNASSIGNED
Twelve out of 51 EC patients developed postoperative pulmonary complications. ALV was smaller while FLV10Gy and FLV20Gy were larger in patients with complications (respectively 3141 ± 858mL vs 3601 ± 635mL,
CONCLUSION UNASSIGNED
Small ALV and increasing FLV exposed to intermediate (10 to 20 Gy) dose are associated to postoperative pulmonary complications. Changes of DLCO occur during nCRT but do not seem to be related to radiation dose to ALV or FLV. This information could attribute towards toxicity risk prediction and reduction strategies for EC.

Identifiants

pubmed: 37643135
doi: 10.1080/0284186X.2023.2251091
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1488-1495

Auteurs

Pieter Populaire (P)

Department of Radiation Oncology, UZ Leuven, Leuven, Belgium.
Department of Oncology, KU Leuven, Leuven, Belgium.

Gilles Defraene (G)

Department of Oncology, KU Leuven, Leuven, Belgium.

Philippe Nafteux (P)

Department of Thoracic Surgery, UZ Leuven, Leuven, Belgium.
Department of Chronic Diseases and Metabolism (CHROMETA), KU Leuven, Leuven, Belgium.

Lieven Depypere (L)

Department of Thoracic Surgery, UZ Leuven, Leuven, Belgium.
Department of Chronic Diseases and Metabolism (CHROMETA), KU Leuven, Leuven, Belgium.

Johnny Moons (J)

Department of Thoracic Surgery, UZ Leuven, Leuven, Belgium.

Sofie Isebaert (S)

Department of Radiation Oncology, UZ Leuven, Leuven, Belgium.
Department of Oncology, KU Leuven, Leuven, Belgium.

Karin Haustermans (K)

Department of Radiation Oncology, UZ Leuven, Leuven, Belgium.
Department of Oncology, KU Leuven, Leuven, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH